COST-EFFECTIVENESS ANALYSIS OF SWITCHING FROM BASAL INSULIN plus ORAL ANTIDIABETICS-GLP1-RA TO IDEGLIRA IN BRAZIL

被引：0

作者：

de Almeida, V ^{[1
]}

Leonart, L. P. ^{[2
]}

Tonin, F. ^{[2
]}

Izar Helfenstein Fonseca, M. ^{[1
]}

Miyamoto Fortes, E. ^{[1
]}

Melo, T. ^{[3
]}

Pititto, L. ^{[1
]}

Gaspar, A. ^{[3
]}

Krakauer, M. ^{[4
]}

机构：

[1] Novo Nordisk, Sao Paulo, SP, Brazil

[2] Heads Hlth, Curitiba, Parana, Brazil

[3] Heads Hlth, Sao Paulo, Brazil

[4] Fac Med ABC, Santo Andre, SP, Brazil

来源：

VALUE IN HEALTH | 2022年 / 25卷 / 07期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

EE295

引用

页码：S391 / S391

页数：1

共 50 条

[1] Long term cost-effectiveness analysis of IDegLira in the treatment of type 2 diabetes patients compared to GLP-1RA added to basal insulin after IDegLira entered the national reimbursement drug list in China
Xiao, Dunming
Weng, Junling
Zhang, Lei
Xing, Chang
Wei, Yan
Chen, Yingyao
PLOS ONE, 2025, 20 (02):
[2] Comment on basal insulin plus bolus insulin or better plus GLP1-RA?
Ritzel, Robert A.
DIABETOLOGIE UND STOFFWECHSEL, 2024, 19 (01) : 30 - 31
[3] COST-EFFECTIVENESS OF TREATING PATIENTS WITH TYPE 2 DIABETES POORLY CONTROLLED ON BASAL INSULIN WITH FIXED-RATIO COMBINATIONS OF BASAL INSULIN AND GLP-1 RECEPTOR AGONISTS IN DENMARK: IDEGLIRA VERSUS IGLARLIXI
Hvid, C.
Parekh, W.
Pohlmann, J.
Hunt, B.
VALUE IN HEALTH, 2018, 21 : S131 - S131
[4] Cost-effectiveness analysis of insulin degludec/liraglutide (IDegLira) vs other basal insulin intensification strategies in Type 2 diabetes patients uncontrolled on basal insulin in a UK setting
Davies, M.
McEwan, P.
Glah, D.
Chubb, B.
Konidaris, G.
Iversen, P.
DIABETIC MEDICINE, 2016, 33 : 155 - 155
[5] A modelled cost-effectiveness analysis of switching patients with poorly controlled type 2 diabetes to insulin detemir from oral antidiabetics or NPH in the Austrian setting; Data from the predictive study
Stechemesser, L.
Weitgasser, R.
Hofmann, M.
Aagren, M.
Mihaljevic, R.
VALUE IN HEALTH, 2008, 11 (03) : A227 - A227
[6] LONG-TERM COST EFFECTIVENESS ANALYSIS OF IDEGLIRA VERSUS GLP-1 ADDED TO BASAL INSULIN AS INTENSIFICATION THERAPIES IN TYPE 2 DIABETES MELLITUS IN SPAIN
Prades, M.
Lizan, L.
Hunt, B.
Ramirez de Arellano, A.
VALUE IN HEALTH, 2016, 19 (03) : A99 - A99
[7] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
Valentine, WJ
Wittrup-Jensen, KU
Häuser, C
Roze, S
DIABETOLOGIA, 2005, 48 : A334 - A334
[8] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
Valentine, WJ
Wittrup-Jensen, KU
Palmer, AJ
Roze, S
DIABETES, 2005, 54 : A609 - A609
[9] Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy
McCrimmon, Rory J.
Lamotte, Mark
Ramos, Mafalda
Alsaleh, Abdul Jabbar Omar
Souhami, Elisabeth
Lew, Elisheva
DIABETES THERAPY, 2021, 12 (12) : 3231 - 3241
[10] Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy
Rory J. McCrimmon
Mark Lamotte
Mafalda Ramos
Abdul Jabbar Omar Alsaleh
Elisabeth Souhami
Elisheva Lew
Diabetes Therapy, 2021, 12 : 3231 - 3241

← 1 2 3 4 5 →